Myth: Generic drugs are lower quality and less safe than brand-name drugs

Journal of Health Services Research and Policy

Volumn 12, Issue 4, 2007, Pages 255-256

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; OMEPRAZOLE; RANITIDINE; SIMVASTATIN;

DRUG INDUSTRY; DRUG QUALITY; DRUG SAFETY; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; SHORT SURVEY;

CANADA; DRUG TOXICITY; DRUGS, GENERIC; HUMANS; QUALITY OF HEALTH CARE;

EID: 36749026309     PISSN: 13558196     EISSN: None     Source Type: Journal    
DOI: 10.1258/135581907782101598     Document Type: Short Survey

References (18)

1. Gaither CA, Kirking DM, Ascione FJ, Welage LS. Consumers' views on generic medications. J Am Pharm Assoc 2001;41:729-36
2. Pereira JA, Holbrook AM, Dolovich L, et al. Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians. Can J Clin Pharmacol 2005;12: e229-39
3. Mott DA, Cline RR. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care 2002;40:662-74
4. Kirking DM, Gaither CA, Ascione FJ, Welage LS. Physicians' individual and organizational views on generic medications. J Am Pharm Assoc 2001;41:718-22
5. Health Canada, Health Products and Food Branch. Access to therapeutic products: the regulatory process in Canada. 2006. See www.hc-sc.gc.ca/ahc-asc/ alt_formats/ hpfb-dgpsa/pdf/pubs/access-therapeutic_acces-therapeutique_ e.pdf
6. Health Canada. The safety and effectiveness of generic drugs. 2006. See www.hc-sc.gc.ca/iyh-vsv/alt_formats/cmcd-dcmc/pdf/genericdrug_e.pdf
7. Canadian Pharmacists Association. Drugs: from research lab to pharmacy shelf. 2007. See www.pharmacists.ca/content/ hcp/resource_centre/ drug_therapeutic_info/pdf/DrugApproval Process.pdf
8. Government of Canada, Department of Justice. Act current to February 28, 2007. Patent Act (R.S., 1985, c. P-4). See www.laws.justice.gc.ca/en/ ShowFullDoc/cs/P-4///en
9. Morgan S, Kozyrskyj A, Metge C, Roos N, Dahl M. Pharmaceuticals: therapeutic interchange and pricing policies. Manitoba Centre for Health Policy, 2003. See www. umanitoba.ca/centres/mchp/reports/pdfs/generic.pdf
10. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med 2005;142:891-7
11. Sprague D. Generics make sense for patients and prescribers. Pract Nurse 2005;29:30-2
12. Grootendorst P. Effects of authorized-generics on Canadian drug prices. Paper presented at the Competition Bureau Intellectual Property Symposium, Ottawa 2007
13. Health Canada. Drug Product Database. 2007. See www. hc-sc.gc.ca/dhp-mps/ prodpharma/databasdon/index_e.html
14. Cavallucci S. The top 200: what's making waves in prescription sales. Pharmacy practice. 2006. See www. imshealthcanada.com/vgn/images/portal/ cit_40000873/3/31/ 80063346The_top_200.pdf
15. Service de l'information aux professionnels. List of medications. 2007. See www.ramq.gouv.qc.ca/en/regie/lois/liste_ med.shtml
16. IMS Health. Prescription drug purchases by Canadian hospitals and pharmacies reach $1657 billion in 2005. 2006. See www.imshealth.com/web/ content/0,3148,77303623_ 63872702_77770096_77808854,00.html
17. Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drugs. Epilepsia 2007;48:464-9
18. Ministry of Health and Long-Term Care. Formulary/CDI, Edition 39. 2007. See www.health.gov.on.ca/english/ providers/program/drugs/edition_39.html